ChromoCure, Inc. (KKUR) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerChromoCure, Inc. (KKUR) trades at $0.000001. ChromoCure, Inc. is a healthcare company specializing in cancer detection systems. Their primary offering is the Chromosomal Scanner Series 200, designed to identify genomic characteristics unique to cancer cells. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for KKUR: KKUR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ChromoCure, Inc. (KKUR) Healthcare & Pipeline Overview
ChromoCure, Inc. focuses on developing and providing cancer detection systems, primarily the Chromosomal Scanner Series 200. This system aims to detect genomic characteristics specific to cancer cells, positioning the company within the niche market of specialized cancer diagnostics and research tools, though its market capitalization is currently $0.
What Is the Investment Thesis for KKUR?
ChromoCure, Inc. presents a high-risk, high-reward investment profile. The company's Chromosomal Scanner Series 200 technology, if validated and successfully commercialized, could represent a significant advancement in cancer detection. However, the company's $0 market capitalization and OTC listing indicate substantial challenges. The success of ChromoCure hinges on its ability to secure funding, complete clinical trials, and gain regulatory approvals. Key value drivers include the successful demonstration of the Chromosomal Scanner's efficacy and the establishment of strategic partnerships. Growth catalysts include potential breakthroughs in cancer therapy research and the expansion of the Chromosomal Scanner's applications. The company's beta of -10.90 suggests an inverse correlation with the market, but this may be due to the stock's illiquidity and speculative nature.
Based on FMP financials and quantitative analysis
KKUR Key Highlights
ChromoCure, Inc. operates in the specialized medical sector, focusing on cancer detection systems.
- The company's primary product is the Chromosomal Scanner Series 200, designed to identify genomic characteristics unique to cancer cells.
- ChromoCure's market capitalization is $0.00B, indicating a micro-cap or nano-cap status.
- The company's beta is -10.90, suggesting an inverse correlation with the market, but this may be due to the stock's illiquidity.
- ChromoCure has a small team of 4 employees, reflecting a lean operational structure.
Who Are KKUR's Competitors?
KKUR is benchmarked below against 3 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ITOC iTonic Holdings Ltd. | $1.50 | -4.46% | $11.0M | — |
| QTEX Inspira Technologies Oxy B.H.N. Ltd. | $1.12 | 0.00% | $75.1M | 45 5-pillar |
| SI SHOULDER INNOVATIONS, INC. | $20.65 | +0.44% | $432M | 34 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KKUR's Key Strengths?
Proprietary Chromosomal Scanner Series 200 technology.
- Focus on non-toxic and non-invasive cancer therapy research.
- Potential for early and accurate cancer detection.
- Experienced team in cancer genomics (assumed).
What Are KKUR's Weaknesses?
Limited financial resources ($0 market cap).
- Small team size (4 employees).
- OTC listing indicates higher risk and lower liquidity.
- Dependence on a single product (Chromosomal Scanner Series 200).
What Are the Key Risks for KKUR?
Limited financial resources and dependence on external funding.
- Competition from established players in the cancer diagnostics market.
- Regulatory hurdles and approval processes.
- Technological obsolescence.
- Low liquidity and price volatility due to OTC listing.
What Are KKUR's Competitive Advantages?
- Proprietary technology in cancer detection.
- Potential intellectual property protection for the Chromosomal Scanner Series 200.
- Specialized expertise in cancer genomics.
- Potential for network effects through collaborations with research institutions.
What Does KKUR Do?
ChromoCure, Inc., originally incorporated as Cyberhand Technologies International, Inc. in 2001, rebranded in June 2009 to reflect its focus on cancer detection technologies. Based in Reno, Nevada, the company develops and provides proprietary cancer detection systems, most notably the Chromosomal Scanner Series 200. This system is designed to measure genomic characteristics found in all cancers but not in normal cells. ChromoCure aims to apply its scientific and technological expertise to develop non-toxic and non-invasive approaches to cancer therapy and cure research. The company's core business revolves around the development, manufacturing, and potential commercialization of its Chromosomal Scanner Series 200. This technology is intended for use in research settings and potentially clinical applications, offering a tool for early and accurate cancer detection. The company's evolution reflects a strategic shift towards specializing in cancer diagnostics and therapeutics, leveraging its technology to address unmet needs in the healthcare sector. With a small team of 4 employees, ChromoCure operates with a lean structure, focusing its resources on research and development efforts.
What Products and Services Does KKUR Offer?
- Develops proprietary cancer detection systems.
- Offers the Chromosomal Scanner Series 200.
- The Chromosomal Scanner Series 200 measures genomic characteristics found in all cancers.
- Applies science and technology to non-toxic cancer therapy research.
- Focuses on non-invasive approaches to cancer therapy.
How Does KKUR Make Money?
- Develops and sells cancer detection systems.
- Generates revenue through the sale of the Chromosomal Scanner Series 200.
- Potentially generates revenue through licensing agreements or partnerships.
- May generate revenue from cancer therapy research and development.
What Industry Does KKUR Operate In?
ChromoCure, Inc. operates within the medical specialties sector, specifically targeting cancer diagnostics and research. The cancer diagnostics market is experiencing growth, driven by increasing cancer incidence, advancements in technology, and a growing demand for early and accurate detection methods. Competitors include companies developing advanced diagnostic tools and therapies, such as ACNV, AHGIF, BTAX, CEVE, and GSRX. ChromoCure's success depends on its ability to differentiate its technology and establish a competitive advantage in this landscape. The company's focus on non-toxic and non-invasive approaches to cancer therapy aligns with current trends in the healthcare industry.
Who Are KKUR's Key Customers?
- Research institutions.
- Cancer centers.
- Hospitals.
- Pharmaceutical companies (potentially).
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
KKUR Latest News
No recent news available for KKUR.
KKUR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for KKUR.
Price Targets
Wall Street price target analysis for KKUR.
KKUR MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for KKUR; grades run from A+ (80-100) to F (below 30).
KKUR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ChromoCure, Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. These companies are not required to adhere to the same rigorous standards as those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Limited regulatory oversight.
- Verify the company's financial statements (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review any available news articles or press releases about the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Check for any regulatory actions or investigations against the company.
- Company has been in operation since 2001.
- Focus on cancer detection systems, a legitimate area of healthcare.
- Development of a specific product (Chromosomal Scanner Series 200).
- Company has a physical headquarters in Reno, Nevada.
- Name change to reflect focus on cancer diagnostics.
ChromoCure, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for KKUR?
ChromoCure, Inc. faces several significant risks. As an OTC-listed company with a $0 market capitalization, it has limited financial resources and is highly dependent on securing external funding. Competition from established players in the cancer diagnostics market poses a substantial threat.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC status and $0 market capitalization.
- The company's future success is highly dependent on securing funding and achieving regulatory approvals.